Skip to content

Janux Therapeutics JANX Restricted Cash

Restricted Cash at other companies

Xencor logo
XencorXNCR
$191K-32.7%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M0.0%
Immunome logo
ImmunomeIMNM
$210K+110%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$7.63M-4.7%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$316K-0.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$3.7M
Operating income-$34.2M+2.0%
Net income-$24.4M-3.6%
EPS (diluted)-$0.39-2.6%

Balance sheet

See full
Cash & equivalents$51.8M-29.7%
Total debt$21.6M-4.6%
Total equity$941.5M-7.0%
Total assets$1.0B-2.1%

Cash flow

See full
Operating cash flow-$12.3M+27.5%
CapEx$273.0K-26.4%
Free cash flow-$12.6M+27.5%

Valuation

See full
Market cap$889.15M-36.3%
Enterprise value$858.89M-36.2%
P/S64.8×-84.8×

Profitability

See full
Operating margin-1,143.1%-65.1pp
Net margin-833.6%+0.9pp
FCF margin-571.6%+98.3pp

Returns & leverage

See full
Return on equity-11.7%+4.1pp
Debt / equity0.0×
Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Janux Therapeutics's restricted cash?
Janux Therapeutics (JANX) reported restricted cash of $816K in Q1 2026.
How has Janux Therapeutics's restricted cash changed year-over-year?
Janux Therapeutics's restricted cash decreased by 0.0% year-over-year, from $816K to $816K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.